Rvltn Bioscnc Stock Price, News & Analysis

Revelation Biosciences, Inc. (warrants trading under the symbol REVBW) is a clinical-stage life sciences company in the pharmaceutical preparation manufacturing industry. According to the company’s public disclosures and SEC filings, Revelation focuses on the development of immunologic-based therapies for the prevention and treatment of disease, along with related diagnostic products. Its warrants are listed on The Nasdaq Stock Market LLC, where each redeemable warrant is exercisable for a fractional share of Revelation’s common stock at a specified exercise price.

The company describes itself as having multiple product candidates in development that target immune pathways. Several of these candidates are intranasal formulations designed to modulate immune responses in the upper respiratory tract or to address allergic conditions. Revelation has also reported work on a rapid at‑home diagnostic intended to detect respiratory viral infections without specialized instrumentation.

Core therapeutic programs

Across multiple press releases, Revelation identifies REVTx‑99b as its lead therapeutic candidate. REVTx‑99b is a proprietary intranasal formulation in development for the management of allergic rhinitis symptoms, including chronic nasal congestion. The company reports that REVTx‑99b is being evaluated in a Phase 1b CLEAR clinical study using a randomized, double‑blind, placebo‑controlled, crossover design. In that study, participants with allergic rhinitis to rye grass pollen receive either study drug or placebo in prophylactic and treatment cohorts around a nasal allergen challenge. The primary endpoint is safety and tolerability, with exploratory or secondary endpoints including Total Nasal Symptom Score and peak nasal inspiratory flow.

Revelation has disclosed mechanistic data for REVTx‑99b from an earlier Phase 1 clinical study. According to the company, the active ingredient upregulates a protein that competes for the native eotaxin receptor, CCR3. By competing for CCR3, this protein is described as preventing eotaxin from recruiting eosinophils and basophils, thereby reducing recruitment of Th2 cells and attenuating the allergic response. This mechanistic focus reflects the company’s broader emphasis on immunologic modulation.

Another program, REVTx‑99a, has been developed for the prevention and treatment of respiratory viral infections. Revelation conducted a Phase 2b viral challenge study (RVL‑VRL01) evaluating intranasal REVTx‑99a as a preventive treatment for H3N2 influenza (influenza A) in healthy adults. In an interim analysis disclosed by the company, REVTx‑99a did not meet its primary efficacy endpoint, and the preliminary results suggested no statistically significant difference versus placebo on the area under the curve of viral load measured by quantitative RT‑PCR from nasopharyngeal swabs. The company has indicated that, despite this outcome, it remains focused on other product candidates.

Additional pipeline and diagnostics

Revelation has reported several other development programs built around immunologic mechanisms:

• REVTx‑200: Described as an intranasal immunomodulator adjunct intended to be used in combination with a traditional intramuscular vaccination to achieve more complete immunity. Company communications note preclinical and Phase 2 viral challenge data suggesting that intranasal REVTx‑200 may positively augment the immune response relative to vaccination alone.
• REVTx‑300: Identified as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease (CKD) and non‑alcoholic steatohepatitis (NASH). Revelation has referenced preclinical work and a PRIME Phase 1b clinical study in chronic kidney disease patients, with top‑line results described as positive in a press release referenced in a 2025 Form 8‑K.
• REVDx‑501: A rapid, home‑use diagnostic test that the company states can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. Revelation has also disclosed that it engaged MedWorld Advisors to facilitate partnering of the REVDx‑501 asset.

Earlier disclosures also reference a proprietary formulation called Gemini, described as Revelation’s formulation of phosphorylated hexaacyl disaccharide (PHAD), a TLR4 agonist intended to stimulate the innate immune response. Gemini‑based programs have included candidates such as Gemini‑SSI for prevention of surgical site infection, Gemini‑AKI for prevention of acute kidney injury, and Gemini‑CKD for chronic kidney disease. These descriptions illustrate the company’s focus on modulating inflammation and innate immunity, though more recent press releases emphasize the REVTx and REVDx programs.

Capital markets and corporate actions

Revelation has reported several capital markets milestones in its public communications. In a 2022 press release, the company noted that it became a publicly traded company through a merger with Petra Acquisition, Inc. and began trading on the Nasdaq Capital Market under the symbol REVB. It also disclosed completing a PIPE financing and subsequent public offerings of common stock and warrants, with proceeds intended to support development of REVTx‑99b, REVTx‑200, REVTx‑300, and other product candidates, as well as working capital and general corporate purposes.

Later SEC filings show that Revelation’s common stock continues to trade under the symbol REVB, while its redeemable warrants trade as REVBW. In 2025, the company filed an 8‑K describing stockholder approval of a reverse stock split authority and the subsequent implementation of a 1‑for‑3 reverse stock split, after which the common stock continued to trade under REVB. The same filing notes proportionate adjustments to outstanding equity awards and warrants, and confirms that REVBW represents redeemable warrants exercisable for fractional shares of common stock at specified exercise prices.

Governance and stockholder matters

Revelation’s SEC filings provide insight into its governance and capital structure. A 2025 definitive proxy statement (DEF 14A) describes a special meeting of stockholders called to approve the reservation and issuance of shares of common stock pursuant to certain Class I Common Stock Warrants, to the extent such issuances may exceed 20% of the company’s total outstanding shares under Nasdaq Rule 5635(d). The same proxy statement outlines stockholder voting procedures, record dates, and the virtual format of the meeting.

Another 2025 Form 8‑K details the results of an annual meeting, including votes on director elections, amendments to the company’s equity incentive plan, advisory votes on executive compensation and its frequency, approval of reverse stock split authority, approval of warrant‑related share issuances in excess of the exchange cap, and a proposal (not approved at the required level) to change the company’s corporate domicile from Delaware to Nevada. These filings indicate an active program of stockholder engagement around capital structure and governance matters.

Clinical‑stage risk profile

As a clinical‑stage life sciences company, Revelation has reported that it does not yet have approved commercial therapies in the areas it is targeting. Its press releases and SEC filings emphasize that product candidates are in various stages of preclinical and clinical development, and that outcomes of studies such as the Phase 1b CLEAR study for REVTx‑99b, the viral challenge study for REVTx‑99a, and the PRIME study for chronic kidney disease are important to the company’s future. The company’s forward‑looking statements highlight uncertainties related to clinical trial enrollment, safety events, regulatory review, and the sufficiency of capital to fund operations.

Understanding REVBW warrants

The REVBW security represents redeemable warrants linked to Revelation’s common stock. SEC filings specify that each warrant is exercisable for a fractional share of common stock at a defined exercise price, and that warrant terms may be adjusted in connection with corporate actions such as reverse stock splits. Investors reviewing REVBW should consult the relevant warrant agreements and prospectus disclosures referenced in the company’s registration statements and 8‑K filings for precise terms, including exercise ratios, prices, and any reset features.

FAQs about Revelation Biosciences and REVBW

The information below addresses common questions based on the company’s public disclosures.